Featured products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC8266	GW-627368X Featured	GW 627368X is a selective prostanoid EP4 receptor competitive antagonist with additional affinity at TP receptors (pKi values are 7.0 and 6.8 in competition radioligand bioassays).
DC2078	GW-7647 Featured	GW 7647 is a potent PPARα agonist with 200-fold selectivity over PPARγ and PPARδ.
DC9904	GW0742 Featured	GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
DC7149	GW1929 Featured	GW1929 is a synthetic peroxisome proliferator-activated receptor-γ (PPARγ) agonist with IC50 of 6.2 nM and 13 nM for human and mouse, respectively.
DC1018	GW-2580 (GW2580) Featured	GW2580 is a selective inhibitor of human c-FMS with IC50 of 30 nM.
DC23142	GW274150 Featured	GW274150 is a novel arginine-competitive, NADPH-dependent iNOS inhibitor that has been identified from a series of acetamide amino acids that have a high selectivity for iNOS vs both eNOS (> 260-fold) and nNOS (> 219-fold) and high bioavailability (> 90%) after oral administration.Target: iNOSin vivo: GW274150 demonstrates a narrow neuroprotective therapeutic window against the toxic actions of 6-OHDA. GW274150 administration leads to a dose-dependent decrease in the number of iNOS-positive cells in the SNc of the 6-OHDA-lesioned animals. The iNOS inhibitor GW274150 fails to produce long-term neuroprotection after its withdrawal in the 6-OHDA-lesioned rat. [1]
DC7837	GW-3965 hydrochloride Featured	GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively.
DC7662	GW4869 Featured	GW4869 is a cell permeable, selective inhibitor of N-SMase (neutral sphingomyelinase).
DC4233	GW501516 Featured	GW501516 is the most selective and potent PPARβ (EC50=1.1nM) agonist that has been demonstrated to be 1,000-fold more selective in comparison to existing subtypes.
DC7980	GW-6604 Featured	GW6604 is a potent and selective ALK-5 inhibitor with potent anticancer activity.
DC7146	GW788388 Featured	GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, also inhibits TGF-β type II receptor and activin type II receptor activities, but does not inhibit BMP type II receptor.
DC10503	GW806742X Featured	GW806742X is a novel VEGFR inhibitor.
DC8609	GW843682X Featured	GW843682X is a cell-permeable thiophene-benzimidazole compound and reversible PLK inhibitor
DC22653	GW-8510 Featured	GW-8510 (GW8510) is a potent, selective inhibitor of CDK2 with IC50 of 10 nM.
DC1086	GW-9508 Featured	GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32.
DC2079	GW-9662 Featured	GW9662 is a selective PPAR antagonist, inhibiting PPARγ, PPARα and PPARδ with IC50 of 3.3 nM, 32 nM and 2 μM, respectively.
DC26080	GX-674 Featured	GX-674 is a potent, selective Nav1.7 inhibitor with IC50 of 0.1 nM.
DC10668	GYY4137 morpholine salt Featured	GYY 4137 is a Water-soluble, slow-releasing hydrogen sulfide donor.
DC7147	GZD824 Featured	GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
DC20118	GZD856 Featured	GZD856 is a novel and orally bioavailable PDGFRα/β inhibitor with IC50s of 68.6 and 136.6 nM, respectively. Anti-lung cancer activities. Also a Bcr-AblT315I inhibitor with IC50s of 19.9 and 15.4 nM for Bcr-Abl and T315I mutant.
DC7835	H-89 2HCl Featured	H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM, 10-fold selective for PKA than PKG, greater than 500-fold selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II.
DC10876	H-151 Featured	H-151(H151) is a novel STING (stimulator of interferon genes) antagonist.
DC10033	H3B-6527 Featured	H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.
DC21105	H3B-8800 Featured	H3B8800 is an orally available splicing modulator that targets spliceosome SF3b complex containing either WT or mutant SF3B1 (binding IC50 of 0.3-2 nM),demonstrates dose-dependent inhibition of both canonical splicing and aberrant splicing induced by mutant SF3B1 in in vitro assays of biochemical splicing, induces lethality in spliceosome-mutant cancer cells.. H3B-8800 potently and preferentially kills spliceosome-mutant epithelial and hematologic tumor cells.
DC8563	HA130 Featured	HA130 is a selective ATX (autotaxin) inhibitor with IC50 of 28 nM.
DC1066	HA14-1 Featured	HA14-1 is a nonpeptidic ligand of a Bcl-2 surface pocket with IC50 of~9 μM.
DC9795	HA-15 Featured	HA15 displayed anti-cancerous activity on all melanoma cells tested, including cells isolated from patients and cells that developed resistance to BRAF inhibitors.
DC10741	HAMNO (NSC111847) Featured	HAMNO is a novel protein interaction inhibitor of replication protein A (RPA).
DC10354	HBX 19818 Featured	HBX 19818 is a selective USP7 inhibitor with IC50 of 28.1 uM .
DC8207	HBX41108 Featured	HBX 41108 is an inhibitor of ubiquitin-specific protease (USP) 7 activity (IC50 = 424 nM).

Featured products

Customized Consultation X

Your information is safe with us. * Required Fields.